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differences were found in the tolerability of BTFC and LTFC in the clinical study. 
National unit costs were applied. The time horizon of the model was 3 months. Sensitiv-
ity analyses were performed to test the results responsiveness to changes in key input 
parameters. RESULTS: Signiﬁ cantly more BTFC patients experienced >15% and 
>20% reduction in IOP compared to LTFC (p = 0.003, P < 0.001). Furthermore, 
3-month health care costs for patients treated with BTFC were lower or comparable 
to those of LTFC in the 10 studied countries. Results were largely insensitive to 
changes in key parameters. The cost-effectiveness analyses revealed that BTFC was 
less costly and more effective than LTFC in 8 out of the 10 studied countries (Spain, 
Italy, Germany, UK, The Netherlands, Norway, Sweden and Denmark) and more 
effective at equal health care costs in France and Finland. Therefore, BTFC was a 
dominating treatment strategy in all countries. CONCLUSIONS: BTFC is an effective 
treatment strategy in terms of lowering IOP and is a cost-effective treatment strategy 
for patients with glaucoma.
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OBJECTIVES: The objective of this study is to determine the daily and yearly cost 
per treatment of innovative biological preparations. In Ukraine live 46 millions inhab-
itans and the appearance of psoriasis is approximately 2%, 920,000 psoriasis patients. 
It is supposed that at 15–20% appearance of middle and severe of psoriasis there are 
138,000–184,000 patients in Ukraine with degree of the illness. Adult patients with 
moderate to severe plaque form of psoriasis who have not clinical responce for other 
systematic therapies, including cyclosporine, metotrexate and PUVA, or when patients 
are contraindicated for these therapies or are intolerant of them. METHODS: Only 
direct medical cost were calculated from Ukrainian database “Compendium” on 
01.05.2010. Annual treatment costs were calculated based on recommended dosesd 
as per Ukrainian Guidelines from 2007. The costs are presented using third-party 
payer’s perspective, i.e. direct cost to the health system is only considered. In the 
analysis there were three strategies of treatment compared: inﬂ iximab, adalimumab 
and ustekinumab. We used the clinical data of inﬂ iximab, adalimumab, ustekinumab 
from published clinical trials (IMPACT, ADEPT, PHOENIX 1). The cost-effectiveness 
analysis from the payer perspective was conducted. RESULTS: The costs for ﬁ rst year 
of therapy of inﬂ iximab per patient with PASI 75 response are 221998,4 UAH (1 USD 
= 7.92 UAH), of adalimumab—815443,2 UAH, and of ustekinumab −235224,0 UAH. 
In model the cost-effectiveness ratios (average cost per one unit PASI 75response) 
amounted to US$454 for inﬂ iximab, US$1745—adalimumab, US$362—ustekinumab. 
CONCLUSIONS: The cost-effectiveness analysis shows that ustekinumab is more 
cost-effective vs. other innovative biologics for severe psoriasis treatment in Ukraine.
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OBJECTIVES: To evaluate cost-effectiveness of ustekinumab vs. inﬂ iximab for severe 
psoriasis in Russia. METHODS: Cost-effectiveness analysis was performed. The evi-
dence of efﬁ cacy and safety of biologic agents was analyzed. Incremental cost-effec-
tiveness ratio (ICER) was calculated for both biologic agent vs. placebo. Drug costs 
were taken into account. Achievement of PASI 75 was considered to be expected 
outcome, data about efﬁ cacy was extracted from clinical trials. RESULTS: There were 
no trials with direct comparison of ustekinumab and inﬁ ximab. Data from separate 
trials showed that efﬁ cacy of ustekinumab was a little lower than inﬂ iximab at 10–12th 
and 24–28th weeks of treatment. On the contrary at 50–52th week of therapy 
ustekinumab becomes a little more effective than inﬂ iximab. Both biologic agents were 
generally well tolerated in most patients. Calculation of expected costs showed that 
ustekinumab was cheaper than inﬂ iximab if similar periods of follow-up are analyzed. 
At 10–12th weeks of therapy ICER for ustekinumab vs. placebo was a little higher 
than ICER for inﬂ iximab vs. placebo. At 24–28th and 50–52th weeks of therapy ICER 
vs. placebo was lower for ustekinumab. CONCLUSIONS: Ustekinumab is an appro-
priate alternative to inﬂ iximab for patients with severe psoriasis.
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OBJECTIVES: A pharmacoeconomic analysis was performed to determine costs, 
consequences and cost-effectiveness of a speciﬁ c brand of partially hydrolyzed 100% 
whey formula manufactured by Nestlé (PHF-W), in the prevention of atopic dermatitis 
(AD) in “at risk” children when compared to standard cow milk formula (CMF) in 
France. METHODS: An economic model depicting treatment pathways, resource 
utilization and costs associated with the treatment of AD in healthy “at risk” French 
newborns who were not exclusively breastfed was constructed for a 12-month time 
horizon, including an initial six months of formula consumption. Model inputs were 
based on the literature, ofﬁ cial formularies and expert opinion, including outcomes 
from a meta-analysis. The treatment pathways included a dietary management 
approach, a medical treatment approach and a combination thereof. The ﬁ nal 
outcome was the expected cost per avoided case of AD, yielding an incremental cost 
per avoided case (ICER) of AD for PHF-W vs. CMF. Outcomes were presented from 
three perspectives: the French Ministry of Health (MOH), the subject’s family and 
society (SOC). a secondary analysis compared PHF-W to extensively hydrolyzed 
formula (EHF) in prevention. RESULTS: A total of 11,291 AD cases were expected 
to be avoided by selecting PHF-W over CMF in a birth cohort of 156,649 at risk 
infants. The base-case analyses yielded expected ICERs of c2684, -c1474 (savings) 
and c1210 from the MOH, family and SOC perspectives, respectively. Cost drivers 
were the formula from the MOH perspectives, time loss from the family perspective, 
and formula but also to a lesser extent time loss from the SOC perspective. PHF-W 
yielded approximately 81Mc savings against EHF in the secondary analysis. One-way 
and probabilistic sensitivity analyses conﬁ rmed the robustness of the model. 
CONCLUSIONS: Under a range of assumptions, this analysis has established the 
cost-effectiveness of PHF-W in the prevention of AD among French infants.
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OBJECTIVES: A pharmacoeconomic analysis was undertaken to determine costs, 
consequences and cost-effectiveness of a brand of partially hydrolyzed 100% whey 
formula manufactured by Nestlé (PHF-W), in the prevention of atopic dermatitis (AD) 
in “at risk” children when compared to extensively hydrolyzed formula (EHF-Whey 
or Casein) in Denmark. METHODS: Based on a 6-month time horizon for formula 
consumption, an economic model was developed synthesizing treatment pathways, 
resource utilization and costs associated with the treatment of AD in healthy “at risk” 
Danish newborns who were not exclusively breastfed. The cost of formula was 
retrieved from market surveys while other model inputs were obtained from the litera-
ture. a meta-analysis of 6 studies that compared the efﬁ cacy of PHF-W (557 patients) 
and EHF (559 and 580 patients for EHF-Whey and EHF-Casein) yielded RR of 
0.75[0.54,1.05] at 0–12 months and 0.80[0.63,1.02] at 0–36 months for PHF-W vs. 
EHF-Whey and RR of 1.06[0.74,1.53] at 0–12 months and 1.13[0.87,1.47] at 0–36 
months for PHF-W vs. EHF-Casein. Given the evidence for non-signiﬁ cant differences 
between PHF-W and EHF, the analytic approach amounted to a cost-minimization 
analysis reporting the difference in formula acquisition costs. In the base case, it was 
assumed that infants consumed the formula of choice for the full 6 months. In a 
sensitivity analysis, subjects consuming PHF, EHF-Whey or EHF-Casein who devel-
oped AD symptoms were switched to EHF-Whey, EHF-Casein or EHF-Whey, respec-
tively. RESULTS: Savings per child receiving formula of DKK 17,033 were generated 
for PHF-W vs. EHF-Whey while savings of DKK 16,974 were observed for PHF-W 
vs. EHF-Casein. The sensitivity analysis yielded a cost saving of DKK 16,800 with 
PHF-W. CONCLUSIONS: Under a range of assumptions, this analysis demonstrated 
the cost-saving nature of PHF-W vs. both types of EHF in the prevention of AD among 
Danish infants. Further sensitivity analyses, including multivariate, are planned for 
conﬁ rmation of results.
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OBJECTIVES: A pharmacoeconomic analysis was undertaken to determine costs, 
consequences and cost-effectiveness of a speciﬁ c brand of partially hydrolyzed 100% 
whey formula manufactured by Nestlé (PHF-W), in the prevention of atopic dermatitis 
(AD) in “at risk” children when compared to standard cow milk formula (CMF) in 
Spain. METHODS: Based on a 12-month time horizon (including 6 months of formula 
consumption), an economic model was developed synthesizing treatment pathways, 
resource utilization and costs associated with the treatment of AD in healthy “at risk” 
Spanish newborns who were not exclusively breastfed. Model inputs were retrieved 
from the literature, ofﬁ cial formularies and expert opinion, including outcomes from 
a meta-analysis. The treatment pathways considered a dietary management approach, 
a medical treatment approach and a combination thereof. The ﬁ nal outcome was the 
expected cost per avoided case of AD, yielding an incremental cost per avoided case 
(ICER) of AD for PHF-W vs. CMF. Outcomes were presented from three perspectives: 
the Spanish Ministry of Health (MOH), the subject’s family and society (SOC). a 
secondary analysis compared PHF-W to extensively hydrolyzed formula (EHF) in 
